Regulatory T cells in HIV immunotherapy

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

• 1  Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol.155(3),1151–1164 (1995).▪▪ Seminal study that first described a subset of T cells that function to maintain self-tolerance by downregulating the immune response to self antigens.
  Medline CASGoogle Scholar
• 2  Kuniyasu Y, Takahashi T, Itoh M, Shimizu J, Toda G, Sakaguchi S: Naturally anergic and suppressive CD25⁺CD4⁺ T cells as a functionally and phenotypically distinct immunoregulatory T-cell subpopulation. Int. Immunol.12(8),1145–1155 (2000).
  Medline CASGoogle Scholar
• 3  Taams L, Akbar AN, Wauben MHM (Eds): Regulatory T Cells In Inflammation. Birkhäuser, Basel, Switzerland (2005).
  Google Scholar
• 4  von Herrath MG, Harrison LC: Antigen-induced regulatory T cells in autoimmunity. Nat. Rev. Immunol.3(3),223–232 (2003).
  Medline CASGoogle Scholar
• 5  Belkaid Y, Tarbell K: Regulatory T cells in the control of host–microorganism interactions (*). Annu. Rev. Immunol.27,551–589 (2009).▪▪ Extensive review on the role of regulatory T cells (Treg) in different infections and includes a discussion of different strategies of Treg manipulation as immunotherapy.
  Medline CASGoogle Scholar
• 6  Sakaguchi S, Miyara M, Costantino CM, Hafler DA: FOXP3⁺ regulatory T cells in the human immune system. Nat. Rev. Immunol.10(7),490–500 (2010).
  Medline CASGoogle Scholar
• 7  Itoh M, Takahashi T, Sakaguchi N et al.: Thymus and autoimmunity: production of CD25⁺CD4⁺ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J. Immunol.162(9),5317–5326 (1999).
  Medline CASGoogle Scholar
• 8  Hori S, Nomura T, Sakaguchi S: Control of regulatory T cell development by the transcription factor Foxp3. Science299(5609),1057–1061 (2003).
  Medline CASGoogle Scholar
• 9  Takahashi T, Tagami T, Yamazaki S et al.: Immunologic self-tolerance maintained by CD25⁺CD4⁺ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med.192(2),303–310 (2000).
  Medline CASGoogle Scholar
• 10  McHugh RS, Whitters MJ, Piccirillo CA et al.: CD4⁺CD25⁺ immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity16(2),311–323 (2002).
  Medline CASGoogle Scholar
• 11  Mandapathil M, Szczepanski MJ, Szajnik M et al.: Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells. J. Biol. Chem.285(36),27571–27580 (2010).
  Medline CASGoogle Scholar
• 12  Mandapathil M, Lang S, Gorelik E, Whiteside TL: Isolation of functional human regulatory T cells (Treg) from the peripheral blood based on the CD39 expression. J. Immunol. Methods.346(1–2),55–63 (2009).▪ Described another method of isolating functionally suppressive Treg without using the intracellular staining with forkhead box (FOX)P3.
  Medline CASGoogle Scholar
• 13  Borsellino G, Kleinewietfeld M, Di Mitri D et al.: Expression of ectonucleotidase CD39 by Foxp3⁺ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood110(4),1225–1232 (2007).
  Medline CASGoogle Scholar
• 14  Barthlott T, Moncrieffe H, Veldhoen M et al.: CD25⁺ CD4⁺ T cells compete with naive CD4⁺ T cells for IL-2 and exploit it for the induction of IL-10 production. Int. Immunol.17(3),279–288 (2005).
  Medline CASGoogle Scholar
• 15  Munn DH, Sharma MD, Mellor AL: Ligation of B7–1/B7–2 by human CD4⁺ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J. Immunol.172(7),4100–4110 (2004).
  Medline CASGoogle Scholar
• 16  Sojka DK, Huang YH, Fowell DJ: Mechanisms of regulatory T-cell suppression – a diverse arsenal for a moving target. Immunology124(1),13–22 (2008).
  Medline CASGoogle Scholar
• 17  Cao X, Cai SF, Fehniger TA et al.: Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity27(4),635–646 (2007).
  Medline CASGoogle Scholar
• 18  Fazekas de St Groth B, Landay AL: Regulatory T cells in HIV infection: pathogenic or protective participants in the immune response? AIDS22(6),671–683 (2008).▪ Lists both murine and human studies in Treg identification and summarizes important Treg studies in HIV infection.
  MedlineGoogle Scholar
• 19  Seddiki N, Kelleher AD: Regulatory T cells in HIV infection: who’s suppressing what? Curr HIV/AIDS Rep.5(1),20–26 (2008).
  MedlineGoogle Scholar
• 20  Kinter A, McNally J, Riggin L, Jackson R, Roby G, Fauci AS: Suppression of HIV-specific T cell activity by lymph node CD25⁺ regulatory T cells from HIV-infected individuals. Proc. Natl Acad. Sci. USA104(9),3390–3395 (2007).▪▪ Described the increased frequency of CD25hiFOXP3+ Treg in lymph nodes compared with Treg in peripheral blood and demonstrated that the lymph nodes Treg exhibited potent HIV-specific suppressive function.
  Medline CASGoogle Scholar
• 21  Krathwohl MD, Schacker TW, Anderson JL: Abnormal presence of semimature dendritic cells that induce regulatory T cells in HIV-infected subjects. J. Infect. Dis.193(4),494–504 (2006).
  Medline CASGoogle Scholar
• 22  Ji J, Cloyd MW: HIV-1 binding to CD4 on CD4⁺CD25⁺ regulatory T cells enhances their suppressive function and induces them to home to, and accumulate in, peripheral and mucosal lymphoid tissues: an additional mechanism of immunosuppression. Int. Immunol.21(3),283–294 (2009).▪▪ Demonstrates how HIV binding to Treg causes a two- to five-fold increase in Treg suppressive activity, an increase in Treg survival, and an accumulation of Treg in peripheral and mucosal lymphoid tissue.
  Medline CASGoogle Scholar
• 23  Becker C, Taube C, Bopp T et al.: Protection from graft-versus-host disease by HIV-1 envelope protein gp120-mediated activation of human CD4⁺CD25⁺ regulatory T cells. Blood114(6),1263–1269 (2009).
  Medline CASGoogle Scholar
• 24  Kinter AL, Horak R, Sion M et al.: CD25⁺ regulatory T cells isolated from HIV-infected individuals suppress the cytolytic and nonlytic antiviral activity of HIV-specific CD8⁺ T cells in vitro.AIDS Res. Hum. Retroviruses23(3),438–450 (2007).
  Medline CASGoogle Scholar
• 25  Thorborn G, Pomeroy L, Isohanni H, Perry M, Peters B, Vyakarnam A: Increased sensitivity of CD4⁺ T-effector cells to CD4⁺CD25⁺ Treg suppression compensates for reduced Treg number in asymptomatic HIV-1 infection. PLoS ONE5(2),E9254 (2010).
  MedlineGoogle Scholar
• 26  Ndhlovu LC, Loo CP, Spotts G, Nixon DF, Hecht FM: FOXP3 expressing CD127lo CD4⁺ T cells inversely correlate with CD38⁺ CD8⁺ T cell activation levels in primary HIV-1 infection. J. Leukoc. Biol.83(2),254–262 (2008).
  Medline CASGoogle Scholar
• 27  Jiao Y, Fu J, Xing S et al.: The decrease of regulatory T cells correlates with excessive activation and apoptosis of CD8⁺ T cells in HIV-1-infected typical progressors, but not in long-term non-progressors. Immunology128(1 Suppl.),E366–E375 (2009).
  MedlineGoogle Scholar
• 28  Giorgi JV, Hultin LE, McKeating JA et al.: Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J. Infect. Dis.179(4),859–870 (1999).▪ One of the first studies correlating immune activation with HIV disease progression.
  Medline CASGoogle Scholar
• 29  Cecchinato V, Tryniszewska E, Ma ZM et al.: Immune activation driven by CTLA-4 blockade augments viral replication at mucosal sites in simian immunodeficiency virus infection. J. Immunol.180(8),5439–5447 (2008).
  Medline CASGoogle Scholar
• 30  Weiss L, Piketty C, Assoumou L et al.: Relationship between regulatory T cells and immune activation in human immunodeficiency virus-infected patients interrupting antiretroviral therapy. PLoS ONE5(7),E11659 (2010).▪ Demonstrated the dual role of Treg in HIV infection: decreasing immune activation and suppressing immune response to the virus.
  MedlineGoogle Scholar
• 31  Brenchley JM, Paiardini M, Knox KS et al.: Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood112(7),2826–2835 (2008).
  Medline CASGoogle Scholar
• 32  Favre D, Lederer S, Kanwar B et al.: Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection. PLoS Pathog.5(2),E1000295 (2009).▪▪ Highly important study demonstrating the negative correlation of T-helper (Th)17:Treg ratio with sustained systemic immune activation in the blood and lymph nodes of pigtailed macaques infected with simian immunodeficiency virus (SIV). The study highlights the possible roles Treg and Th17 cells play in lentiviral infections.
  MedlineGoogle Scholar
• 33  Prendergast A, Prado JG, Kang YH et al.: HIV-1 infection is characterized by profound depletion of CD161⁺ Th17 cells and gradual decline in regulatory T cells. AIDS24(4),491–502 (2010).
  MedlineGoogle Scholar
• 34  Favre D, Mold J, Hunt PW et al.: Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of Th17 to regulatory T cells in HIV disease. Sci. Transl. Med.2(32),32ra36 (2010).▪▪ Important follow-up study investigating the role of indoleamine 2,3 deoxygenase in altering the Th17/Treg balance and in the chronic inflammatory state observed in progressive HIV disease.
  MedlineGoogle Scholar
• 35  Cao W, Jamieson BD, Hultin LE, Hultin PM, Detels R: Regulatory T cell expansion and immune activation during untreated HIV type 1 infection are associated with disease progression. AIDS Res. Hum. Retroviruses25(2),183–191 (2009).▪ Case–control study results showed positive correlation of Treg expansion leading to immune activation and disease progression.
  Medline CASGoogle Scholar
• 36  Kovacs JA, Baseler M, Dewar RJ et al.: Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. N. Engl. J. Med.(9),567–575 (1995).
  Google Scholar
• 37  Kovacs JA, Vogel S, Albert JM et al.: Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N. Engl. J. Med.335(18),1350–1356 (1996).
  Medline CASGoogle Scholar
• 38  Vogler MA, Teppler H, Gelman R et al.: Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4⁺ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248). J. Acquir. Immune Defic. Syndr.36(1),576–587 (2004).
  Medline CASGoogle Scholar
• 39  Goujard C, Marcellin F, Hendel-Chavez H et al.: Interruption of antiretroviral therapy initiated during primary HIV-1 infection: impact of a therapeutic vaccination strategy combined with interleukin (IL)-2 compared with IL-2 alone in the ANRS 095 randomized study. AIDS Res. Hum. Retroviruses23(9),1105–1113 (2007).
  Medline CASGoogle Scholar
• 40  Abrams D, Levy Y, Losso MH et al.: Interleukin-2 therapy in patients with HIV infection. N. Engl. J. Med.361(16),1548–1559 (2009).
  Medline CASGoogle Scholar
• 41  Asmuth DM, Murphy RL, Rosenkranz SL et al.: Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon α-2a in HIV-1-monoinfected participants: a Phase II clinical trial. J. Infect. Dis.201(11),1686–1696 (2010).
  Medline CASGoogle Scholar
• 42  Levy Y, Lacabaratz C, Weiss L et al.: Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J. Clin. Invest.119(4),997–1007 (2009).
  Medline CASGoogle Scholar
• 43  Sereti I, Dunham RM, Spritzler J et al.: IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood113(25),6304–6314 (2009).
  Medline CASGoogle Scholar
• 44  Day CL, Kaufmann DE, Kiepiela P et al.: PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature443(7109),350–354 (2006).
  Medline CASGoogle Scholar
• 45  Blackburn SD, Shin H, Haining WN et al.: Coregulation of CD8⁺ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol.10(1),29–37 (2009).
  Medline CASGoogle Scholar
• 46  Macatangay BJ, Rinaldo CR: PD-1 blockade: a promising immunotherapy for HIV? Cellscience5(4),61–65 (2009).
  MedlineGoogle Scholar
• 47  Kassu A, Marcus RA, D’Souza MB et al.: Regulation of virus-specific CD4⁺ T cell function by multiple costimulatory receptors during chronic HIV infection. J. Immunol.185(5),3007–3018 (2010).▪ Investigated the relationship of different costimulatory receptors with HIV replication and found that expression of programmed death receptor (PD)-1, cytotoxic T lymphocyte-associated antigen (CTLA)-4 and T-cell immunoglobulin and mucin domain-containing molecule (TIM)-3 together strongly correlated with plasma viremia.
  Medline CASGoogle Scholar
• 48  Velu V, Titanji K, Zhu B et al.: Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature458(7235),206–210 (2009).▪ First in vivo study showing the enhancement of SIV-specific immune response after administering a PD-1 antibody to SIV-infected macaques.
  Medline CASGoogle Scholar
• 49  Breton G, Yassine-Diab B, Cohn L et al.: siRNA knockdown of PD-L1 and PD-L2 in monocyte-derived dendritic cells only modestly improves proliferative responses to Gag by CD8⁺ T cells from HIV-1-infected individuals. J. Clin. Immunol.29(5),637–645 (2009).
  Medline CASGoogle Scholar
• 50  Connolly NC, Whiteside TL, Wilson C, Kondragunta V, Rinaldo CR, Riddler SA: Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals. Clin. Vaccine Immunol.15(2),284–292 (2008).
  Medline CASGoogle Scholar
• 51  Routy JP, Boulassel MR, Yassine-Diab B et al.: Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy. Clin. Immunol.134(2),140–147 (2010).
  Medline CASGoogle Scholar
• 52  Lu W, Arraes LC, Ferreira WT, Andrieu JM: Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat. Med.10(12),1359–1365 (2004).
  Medline CASGoogle Scholar
• 53  Garcia F, Lejeune M, Climent N et al.: Therapeutic immunization with dendritic cells loaded with heat-inactivated autologous HIV-1 in patients with chronic HIV-1 infection. J. Infect. Dis.191(10),1680–1685 (2005).
  Medline CASGoogle Scholar
• 54  Wei S, Kryczek I, Edwards RP et al.: Interleukin-2 administration alters the CD4⁺FOXP3⁺ T-cell pool and tumor trafficking in patients with ovarian carcinoma. Cancer Res.67(15),7487–7494 (2007).▪ Cancer study showing proliferation of existent Treg after administration of IL-2 therapy together with increased C-X-C chemokine receptor-4 expression allowing them to migrate to the tumor.
  Medline CASGoogle Scholar
• 55  Weiss L, Letimier FA, Carriere M et al.: In vivo expansion of naive and activated CD4⁺CD25⁺FOXP3⁺ regulatory T cell populations in interleukin-2-treated HIV patients. Proc. Natl Acad. Sci. USA107(23),10632–10637 (2010).▪▪ Demonstrated expansion of the Treg subset after IL-2 therapy, which the authors hypothesize is a possible explanation for the higher relative risk of progression to AIDS in subjects who had greater CD4 count expansion while on IL-2 therapy.
  Medline CASGoogle Scholar
• 56  Ndhlovu LC, Sinclair E, Epling L et al.: IL-2 immunotherapy to recently HIV-1 infected adults maintains the numbers of IL-17 expressing CD4⁺ T (T(H)17) cells in the periphery. J. Clin. Immunol.30(5),681–692 (2010).
  Medline CASGoogle Scholar
• 57  Levings MK, Sangregorio R, Galbiati F, Squadrone S, de Waal Malefyt R, Roncarolo MG: IFN-α and IL-10 induce the differentiation of human type 1 T regulatory cells. J. Immunol.166(9),5530–5539 (2001).
  Medline CASGoogle Scholar
• 58  Luik A, Knapp S, Thursz M, Thomas HC, Schlaak JF: Autoregulatory role of interleukin-10 in hepatitis C patients treated with IFN-α. J. Interferon Cytokine Res.24(10),585–593 (2004).
  Medline CASGoogle Scholar
• 59  Franceschini D, Paroli M, Francavilla V et al.: PD-L1 negatively regulates CD4⁺CD25⁺Foxp3⁺ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J. Clin. Invest.119(3),551–564 (2009).
  Medline CASGoogle Scholar
• 60  Radziewicz H, Dunham RM, Grakoui A: PD-1 tempers Tregs in chronic HCV infection. J. Clin. Invest.119(3),450–453 (2009).
  Medline CASGoogle Scholar
• 61  Sachdeva M, Fischl MA, Pahwa R, Sachdeva N, Pahwa S: Immune exhaustion occurs concomitantly with immune activation and decrease in regulatory T cells in viremic chronically HIV-1-infected patients. J. Acquir. Immune Defic. Syndr.54(5),447–454 (2010).▪ Showed that in viremic HIV patients, Treg frequency negatively correlated with both immune activation (HLA-DR and CD38 coexpression) and immune exhaustion (expression of PD-1).
  Medline CASGoogle Scholar
• 62  Amarnath S, Costanzo CM, Mariotti J et al.: Regulatory T cells and human myeloid dendritic cells promote tolerance via programmed death ligand-1. PLoS Biol.8(2),E1000302 (2010).▪ Demonstrated an important mechanism of suppression by Treg, which is to upregulate the expression of PD-L1 in myeloid dendritic cells.
  MedlineGoogle Scholar
• 63  Macatangay BJ, Szajnik ME, Whiteside TL, Riddler SA, Rinaldo CR: Regulatory T cell suppression of Gag-specific CD8 T cell polyfunctional response after therapeutic vaccination of HIV-1-infected patients on ART. PLoS ONE5(3),e9852 (2010).▪ Demonstrated increase in HIV-specific Treg suppressive function in HIV subjects after receiving an autologous dendritic cell HIV vaccine. The removal of Treg led to an increase on CD8 T-cell polyfunctional response to Gag peptide.
  MedlineGoogle Scholar
• 64  Banerjee DK, Dhodapkar MV, Matayeva E, Steinman RM, Dhodapkar KM: Expansion of FOXP3 high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood108(8),2655–2661 (2006).▪ Cancer study that demonstrated that dendritic cells can induce the expansion of Treg and is dependent on cell–cell contact.
  Medline CASGoogle Scholar
• 65  Berntsen A, Brimnes MK, thor Straten P, Svane IM: Increase of circulating CD4⁺CD25highFoxp3⁺ regulatory T cells in patients with metastatic renal cell carcinoma during treatment with dendritic cell vaccination and low-dose interleukin-2. J. Immunother.33(4),425–434 (2010).
  Medline CASGoogle Scholar
• 66  Onishi Y, Fehervari Z, Yamaguchi T, Sakaguchi S: Foxp3⁺ natural regulatory T cells preferentially form aggregates on dendritic cells in vitro and actively inhibit their maturation. Proc. Natl Acad. Sci. USA105(29),10113–10118 (2008).▪ Another important study demonstrating Treg and dendritic cell interactions. Treg were shown to aggregate around the dendritic cells and exert a CD80/86 down modulating effect, even in the presence of strong dendritic cell-maturing stimuli.
  Medline CASGoogle Scholar
• 67  O’Gorman WE, Dooms H, Thorne SH et al.: The initial phase of an immune response functions to activate regulatory T cells. J. Immunol.183(1),332–339 (2009).▪▪ Important study demonstrating the activation of Treg as the initial event in the T-cell immune response.
  MedlineGoogle Scholar
• 68  Valentin A, von Gegerfelt A, Rosati M et al.: Repeated DNA therapeutic vaccination of chronically SIV-infected macaques provides additional virological benefit. Vaccine8(8),1962–1974 (2010).
  Google Scholar
• 69  Rech AJ, Vonderheide RH: Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann. NY Acad. Sci.1174,99–106 (2009).
  Medline CASGoogle Scholar
• 70  Jacobs JF, Punt CJ, Lesterhuis WJ et al.: Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a Phase I/II study in metastatic melanoma patients. Clin. Cancer Res.16(20),5067–5078 (2010).
  Medline CASGoogle Scholar
• 71  Saha A, Chatterjee SK: Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer. Scand. J. Immunol.71(2),70–82 (2010).
  Medline CASGoogle Scholar
• 72  Coe D, Begom S, Addey C, White M, Dyson J, Chai JG: Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy. Cancer Immunol. Immunother.59(9),1367–1377 (2010).
  Medline CASGoogle Scholar
• 73  Morrow MP, Pankhong P, Laddy DJ et al.: Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood113(23),5868–5877 (2009).
  Medline CASGoogle Scholar
• 74  Hryniewicz A, Boasso A, Edghill-Smith Y et al.: CTLA-4 blockade decreases TGF-β, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques. Blood108(12),3834–3842 (2006).
  Medline CASGoogle Scholar
• 75  Sarnaik AA, Weber JS: Recent advances using anti-CTLA-4 for the treatment of melanoma. Cancer J.15(3),169–173 (2009).
  Medline CASGoogle Scholar
• 76  Hershfield MS. New insights into adenosine-receptor-mediated immunosuppression and the role of adenosine in causing the immunodeficiency associated with adenosine deaminase deficiency. Eur. J. Immunol.35(1),25–30 (2005).
  Medline CASGoogle Scholar
• 77  Deaglio S, Dwyer KM, Gao W et al.: Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J. Exp. Med.204(6),1257–1265 (2007).
  Medline CASGoogle Scholar
• 78  Douek DC, Roederer M, Koup RA: Emerging concepts in the immunopathogenesis of AIDS. Annu. Rev. Med.60,471–484 (2009).▪▪ Excellent review of recent developments in HIV immunopathogenesis, which includes chronic immune activation and T-cell dysfunction.
  Medline CASGoogle Scholar
• 79  Thomson CW, Lee BP, Zhang L: Double-negative regulatory T cells: non-conventional regulators. Immunol. Res.35(1–2),163–178 (2006).
  Medline CASGoogle Scholar
• 80  Bouaziz JD, Yanaba K, Tedder TF: Regulatory B cells as inhibitors of immune responses and inflammation. Immunol. Rev.224,201–214 (2008).
  Medline CASGoogle Scholar
• 81  Gabrilovich DI, Nagaraj S: Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol.9(3),162–174 (2009).
  Medline CASGoogle Scholar
• 82  Scholzen A, Minigo G, Plebanski M: Heroes or villains? T regulatory cells in malaria infection. Trends Parasitol.26(1),16–25 (2010).
  Medline CASGoogle Scholar
• 83  He XY, Xiao L, Chen HB et al.: T regulatory cells and Th1/Th2 cytokines in peripheral blood from tuberculosis patients. Eur. J. Clin. Microbiol. Infect. Dis.29(6),643–650 (2010).
  Medline CASGoogle Scholar
• 84  Sturm N, Thelu MA, Camous X et al.: Characterization and role of intra-hepatic regulatory T cells in chronic hepatitis C pathogenesis. J. Hepatol.53(1),25–35 (2010).
  Medline CASGoogle Scholar
• 85  Rallon NI, Barreiro P, Soriano V, Garcia-Samaniego J, Lopez M, Benito JM: Elevated TGF-β1 levels might protect HCV/HIV-coinfected patients from liver fibrosis. Eur. J. Clin. Invest. DOI: 10.1111/j.1365-2362.2010.02381 (2010) (Epub ahead of print).
  MedlineGoogle Scholar